The affordable growth strategy sits between pure value investing and chasing high-growth names at any cost. It targets companies that demonstrate strong revenue and earnings momentum while still trading at multiples that leave room for further upside, without demanding perfection in profitability or financial health. This approach is especially relevant in a market where the S&P 500’s long-term trend is neutral but the short-term trend shows positive momentum—a climate where selectivity matters more than broad exposure.
One stock that recently came up through an affordable growth screen is Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). The company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs, anchored by its lead product ZORYVE, a once-daily topical PDE4 inhibitor approved for plaque psoriasis and atopic dermatitis.
A Strong Growth Profile
The growth component is where ARQT stands out most clearly. The ChartMill fundamental report shows a Growth rating of 7 out of 10, driven by both past performance and forward expectations. Over the last year, earnings per share improved by 97.12% and revenue jumped 95.29%, with average annual revenue growth over the past several years coming in at an impressive 367.11%. Looking ahead, analysts expect EPS to grow at an average annual rate of 88.27% and revenue to expand by 24.01% per year.
These figures are critical for the affordable growth framework. The screen specifically looks for companies where top-line expansion is both realized and sustainable, and ARQT’s trajectory fits that bill. A detailed breakdown of these metrics is available in the full fundamental analysis report.
Valuation: Not Cheap in Isolation, but Competitive in Context
On the surface, valuation looks tricky. ARQT’s Price/Forward Earnings ratio sits at 27.20, which is above the S&P 500 average of 21.32 and looks expensive in absolute terms. However, the affordable growth lens considers valuation relative to industry peers and to growth expectations.
Against its biotechnology industry, ARQT is cheaper than 91.81% of comparable companies on a forward earnings basis. Its Enterprise Value to EBITDA ratio is also favorable relative to the industry, and the Price/Free Cash Flow ratio ranks as cheaper than 89.47% of peers. Perhaps most tellingly, the PEG ratio—which adjusts the P/E for expected earnings growth—indicates a rather cheap valuation given that earnings are projected to grow by 148.68% in the coming years.
This combination means investors are not paying a premium for growth that may not materialize. The neutral Valuation rating of 5 out of 10 reflects the fact that while ARQT is not a deep value stock, it is reasonably priced relative to the growth it delivers.
Profitability and Health: Decent Foundations
No affordable growth screen demands flawless profitability, but it does require that the company is not in financial distress. ARQT scores a Profitability rating of 5 out of 10, supported by improving margins. Gross margin stands at 90.94%—better than nearly 93% of industry peers—and operating margin of 0.77% also ranks well above most competitors, despite the fact that the company still reports negative net income.
On the health side, the Health rating is also 5 out of 10, but the underlying data tells a more nuanced story. The Altman-Z score of 6.05 indicates low bankruptcy risk, outperforming 74.46% of the industry. The current ratio of 2.68 and quick ratio of 2.46 suggest the company can comfortably meet its short-term obligations. The Debt/Equity ratio of 0.54 indicates modest leverage, though the Debt to Free Cash Flow ratio is higher at 6.47, which is a point to monitor as the company continues to scale.
These figures confirm that ARQT is not carrying excessive risk, which is exactly what the affordable growth screen requires: enough financial stability to support future growth without relying on aggressive borrowing.
Finding More Affordable Growth Opportunities
The combination of strong growth, reasonable valuation relative to the industry, and adequate financial health makes ARQT a candidate worth watching for investors who want growth without paying peak multiples. This isn’t a stock for income seekers—there are no dividends—but it fits the profile of a company that is scaling its commercial products and moving toward profitability.
For those interested in exploring similar setups, the Affordable Growth screen provides a starting point to identify more stocks that combine solid growth metrics with sensible valuations and acceptable health and profitability scores.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum
The affordable growth strategy sits between pure value investing and chasing high-growth names at any cost. It targets companies that demonstrate strong revenue and earnings momentum while still trading at multiples that leave room for further upside, without demanding perfection in profitability or financial health. This approach is especially relevant in a market where the S&P 500’s long-term trend is neutral but the short-term trend shows positive momentum—a climate where selectivity matters more than broad exposure.
One stock that recently came up through an affordable growth screen is Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT). The company is focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs, anchored by its lead product ZORYVE, a once-daily topical PDE4 inhibitor approved for plaque psoriasis and atopic dermatitis.
A Strong Growth Profile
The growth component is where ARQT stands out most clearly. The ChartMill fundamental report shows a Growth rating of 7 out of 10, driven by both past performance and forward expectations. Over the last year, earnings per share improved by 97.12% and revenue jumped 95.29%, with average annual revenue growth over the past several years coming in at an impressive 367.11%. Looking ahead, analysts expect EPS to grow at an average annual rate of 88.27% and revenue to expand by 24.01% per year.
These figures are critical for the affordable growth framework. The screen specifically looks for companies where top-line expansion is both realized and sustainable, and ARQT’s trajectory fits that bill. A detailed breakdown of these metrics is available in the full fundamental analysis report.
Valuation: Not Cheap in Isolation, but Competitive in Context
On the surface, valuation looks tricky. ARQT’s Price/Forward Earnings ratio sits at 27.20, which is above the S&P 500 average of 21.32 and looks expensive in absolute terms. However, the affordable growth lens considers valuation relative to industry peers and to growth expectations.
Against its biotechnology industry, ARQT is cheaper than 91.81% of comparable companies on a forward earnings basis. Its Enterprise Value to EBITDA ratio is also favorable relative to the industry, and the Price/Free Cash Flow ratio ranks as cheaper than 89.47% of peers. Perhaps most tellingly, the PEG ratio—which adjusts the P/E for expected earnings growth—indicates a rather cheap valuation given that earnings are projected to grow by 148.68% in the coming years.
This combination means investors are not paying a premium for growth that may not materialize. The neutral Valuation rating of 5 out of 10 reflects the fact that while ARQT is not a deep value stock, it is reasonably priced relative to the growth it delivers.
Profitability and Health: Decent Foundations
No affordable growth screen demands flawless profitability, but it does require that the company is not in financial distress. ARQT scores a Profitability rating of 5 out of 10, supported by improving margins. Gross margin stands at 90.94%—better than nearly 93% of industry peers—and operating margin of 0.77% also ranks well above most competitors, despite the fact that the company still reports negative net income.
On the health side, the Health rating is also 5 out of 10, but the underlying data tells a more nuanced story. The Altman-Z score of 6.05 indicates low bankruptcy risk, outperforming 74.46% of the industry. The current ratio of 2.68 and quick ratio of 2.46 suggest the company can comfortably meet its short-term obligations. The Debt/Equity ratio of 0.54 indicates modest leverage, though the Debt to Free Cash Flow ratio is higher at 6.47, which is a point to monitor as the company continues to scale.
These figures confirm that ARQT is not carrying excessive risk, which is exactly what the affordable growth screen requires: enough financial stability to support future growth without relying on aggressive borrowing.
Finding More Affordable Growth Opportunities
The combination of strong growth, reasonable valuation relative to the industry, and adequate financial health makes ARQT a candidate worth watching for investors who want growth without paying peak multiples. This isn’t a stock for income seekers—there are no dividends—but it fits the profile of a company that is scaling its commercial products and moving toward profitability.
For those interested in exploring similar setups, the Affordable Growth screen provides a starting point to identify more stocks that combine solid growth metrics with sensible valuations and acceptable health and profitability scores.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own due diligence before making investment decisions.
Read full article here »